Want to see XERS full AI Analyst Report?
Xeris Pharmaceuticals (XERS) Ratios
Xeris Pharmaceuticals Ratios
XERS's free cash flow for Q2 2026 was $8.05M. For the 2026 fiscal year, XERS's free cash flow was decreased by $-209.00K and operating cash flow was $8.26M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.19 | 1.67 | 1.64 | 2.54 | 1.80 |
| Quick Ratio | 1.57 | 1.19 | 1.23 | 2.20 | 1.57 |
| Cash Ratio | 1.01 | 0.71 | 0.71 | 1.66 | 0.85 |
| Solvency Ratio | 0.03 | -0.12 | -0.15 | -0.27 | -0.58 |
| Operating Cash Flow Ratio | 0.26 | -0.37 | -0.49 | -1.40 | -1.30 |
| Short-Term Operating Cash Flow Coverage | 4.59 | -2.45 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -129.53M | $ -185.01M | $ -173.12M | $ -112.52M | $ -66.53M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.10 | 0.84 | 0.71 | 0.57 | 0.29 |
| Debt-to-Equity Ratio | 2.76 | -9.17 | -33.79 | 4.38 | 0.92 |
| Debt-to-Capital Ratio | 0.73 | 1.12 | 1.03 | 0.81 | 0.48 |
| Long-Term Debt-to-Capital Ratio | 0.70 | 1.16 | 1.04 | 0.81 | 0.48 |
| Financial Leverage Ratio | 28.02 | -10.91 | -47.57 | 7.62 | 3.20 |
| Debt Service Coverage Ratio | 0.36 | -0.24 | -0.85 | -4.81 | -15.83 |
| Interest Coverage Ratio | 0.86 | -1.01 | -1.65 | -5.81 | -16.04 |
| Debt to Market Cap | 0.03 | 0.47 | 0.59 | 1.04 | 0.38 |
| Interest Debt Per Share | 0.42 | 2.08 | 1.86 | 1.56 | 1.21 |
| Net Debt to EBITDA | -5.77 | -14.28 | -6.81 | -1.10 | -0.18 |
| Profitability Margins | |||||
| Gross Profit Margin | 81.70% | 81.86% | 82.52% | 79.47% | 73.14% |
| EBIT Margin | 0.19% | -13.11% | -22.51% | -74.36% | -233.00% |
| EBITDA Margin | 4.36% | -6.89% | -14.48% | -62.87% | -229.21% |
| Operating Profit Margin | 8.53% | -16.57% | -26.85% | -74.32% | -232.22% |
| Pretax Profit Margin | 0.19% | -28.12% | -38.74% | -87.15% | -247.48% |
| Net Profit Margin | 0.19% | -27.00% | -37.98% | -85.86% | -247.48% |
| Continuous Operations Profit Margin | 0.19% | -27.00% | -37.98% | -85.86% | -247.48% |
| Net Income Per EBT | 100.00% | 96.03% | 98.03% | 98.52% | 100.00% |
| EBT Per EBIT | 2.23% | 169.72% | 144.29% | 117.26% | 106.57% |
| Return on Assets (ROA) | 0.14% | -16.97% | -19.30% | -27.48% | -40.32% |
| Return on Equity (ROE) | 4.05% | 185.16% | 917.94% | -209.49% | -128.87% |
| Return on Capital Employed (ROCE) | 9.09% | -15.11% | -19.35% | -30.25% | -51.11% |
| Return on Invested Capital (ROIC) | 8.89% | -13.25% | -18.68% | -29.63% | -51.11% |
| Return on Tangible Assets | 0.20% | -27.24% | -32.77% | -47.08% | -81.79% |
| Earnings Yield | 0.04% | -11.02% | -19.24% | -52.48% | -53.00% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.72 | 5.02 | 4.18 | 3.58 | 2.84 |
| Payables Turnover | 17.36 | 16.08 | 2.48 | 4.91 | 1.49 |
| Inventory Turnover | 0.78 | 0.76 | 0.74 | 0.92 | 0.74 |
| Fixed Asset Turnover | 10.79 | 7.20 | 5.62 | 11.60 | 7.48 |
| Asset Turnover | 0.76 | 0.63 | 0.51 | 0.32 | 0.16 |
| Working Capital Turnover Ratio | 2.95 | 3.17 | 1.88 | 1.25 | 0.53 |
| Cash Conversion Cycle | 512.11 | 527.36 | 434.80 | 426.67 | 380.46 |
| Days of Sales Outstanding | 63.85 | 72.64 | 87.28 | 102.07 | 128.48 |
| Days of Inventory Outstanding | 469.29 | 477.41 | 494.88 | 398.88 | 496.55 |
| Days of Payables Outstanding | 21.02 | 22.69 | 147.36 | 74.28 | 244.58 |
| Operating Cycle | 533.14 | 550.05 | 582.16 | 500.95 | 625.03 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.18 | -0.25 | -0.34 | -0.76 | -1.30 |
| Free Cash Flow Per Share | 0.17 | -0.26 | -0.36 | -0.76 | -1.31 |
| Dividend Paid and CapEx Coverage Ratio | 41.13 | -42.60 | -20.78 | -196.36 | -196.36 |
| Capital Expenditure Coverage Ratio | 41.13 | -42.60 | -20.78 | -196.36 | -196.36 |
| Operating Cash Flow Coverage Ratio | 0.76 | -0.14 | -0.21 | -0.52 | -1.17 |
| Operating Cash Flow to Sales Ratio | 0.10 | -0.18 | -0.29 | -0.93 | -2.07 |
| Free Cash Flow Yield | 2.22% | -7.61% | -15.23% | -57.33% | -44.66% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 2242.86 | -9.16 | -5.20 | -1.91 | -1.89 |
| Price-to-Sales (P/S) Ratio | 4.32 | 2.45 | 1.97 | 1.64 | 4.67 |
| Price-to-Book (P/B) Ratio | 92.00 | -16.80 | -47.71 | 3.99 | 2.43 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 45.09 | -13.15 | -6.56 | -1.74 | -2.24 |
| Price-to-Operating Cash Flow Ratio | 43.99 | -13.45 | -6.88 | -1.75 | -2.25 |
| Price-to-Earnings Growth (PEG) Ratio | -22.22 | 0.52 | 0.15 | 0.03 | 0.07 |
| Enterprise Value Multiple | 93.32 | -49.83 | -20.45 | -3.70 | -2.22 |
| Enterprise Value | 1.19B | 697.39M | 485.28M | 256.48M | 252.35M |
| EV to EBITDA | 93.32 | -49.83 | -20.45 | -3.70 | -2.22 |
| EV to Sales | 4.06 | 3.43 | 2.96 | 2.33 | 5.09 |
| EV to Free Cash Flow | 42.47 | -18.43 | -9.85 | -2.48 | -2.44 |
| EV to Operating Cash Flow | 41.43 | -18.86 | -10.32 | -2.49 | -2.45 |
| Tangible Book Value Per Share | -0.61 | -1.03 | -1.01 | -0.72 | -0.75 |
| Shareholders’ Equity Per Share | 0.09 | -0.20 | -0.05 | 0.33 | 1.21 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.04 | 0.02 | 0.01 | 0.00 |
| Revenue Per Share | 1.82 | 1.38 | 1.19 | 0.81 | 0.63 |
| Net Income Per Share | 0.00 | -0.37 | -0.45 | -0.70 | -1.55 |
| Tax Burden | 1.00 | 0.96 | 0.98 | 0.99 | 1.00 |
| Interest Burden | 1.00 | 2.15 | 1.72 | 1.17 | 1.06 |
| Research & Development to Revenue | 0.11 | 0.13 | 0.14 | 0.19 | 0.51 |
| SG&A to Revenue | 0.62 | 0.81 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.08 | 0.09 | 0.07 | 0.11 | 0.23 |
| Income Quality | 51.67 | 0.67 | 0.76 | 1.09 | 0.84 |
Currency in USD